We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $2.19B Turnover 34.18%
1-Year Est. Return 374.99%
This Fund
S&P 500
This Quarter Est. Return
+22.32%
1 Year Est. Return
+374.99%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.19B
AUM Growth
+$487M
Cap. Flow
+$166M
Cap. Flow %
7.61%
Top 10 Hldgs %
40.83%
Holding
354
New
43
Increased
102
Reduced
64
Closed
78
Avg Time Held Equity + Options
0.9 years
Top 10 Avg Time Held Equity + Options
1.1 years
Top 20 Avg Time Held Equity + Options
0.9 years
Avg Time Held Equity only
0.9 years
Top 10 Avg Time Held Equity only
1.3 years
Top 20 Avg Time Held Equity only
0.9 years

Top Buys

Rank Stock Value
1
ABVX icon
Abivax
ABVX
+$46.5M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$38.5M
3
ZLAB icon
Zai Lab
ZLAB
+$38.4M
4
AGIO icon
Agios Pharmaceuticals
AGIO
+$34.8M
5
EDIT icon
Editas Medicine
EDIT
+$26M

Top Sells

Rank Stock Value
1
TERN icon
Terns Pharmaceuticals
TERN
+$48.2M
2
BEAM icon
Beam Therapeutics
BEAM
+$34.5M
3
SRRK icon
Scholar Rock
SRRK
+$20M
4
DNLI icon
Denali Therapeutics
DNLI
+$17.3M
5
CYTK icon
Cytokinetics
CYTK
+$12.5M

Sector Composition

Rank Sector Weight
1 Healthcare 86.67%
2 Miscellaneous 11.02%
3 Financials 2.15%
4 Real Estate 0.05%
5 Communication Services 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
LRMR icon
176
Larimar Therapeutics
LRMR
$217M
$832K 0.04%
272,745
+220,000
+417% +$874K
2025 Q2
4 quarters
VERA icon
177
Vera Therapeutics
VERA
$1.93B
$786K 0.04%
18,322
+2,289
+14% +$85.3K
2025 Q4
2 quarters
ADGM icon
178
Adagio Medical Holdings
ADGM
$2.44M
$785K 0.04%
1,205,447
– –
2025 Q4
2 quarters
RNA icon
179
Atrium Therapeutics
RNA
$131M
$776K 0.04%
57,688
– –
2026 Q1
1 quarter
TXMD icon
180
TherapeuticsMD
TXMD
$22.8M
$757K 0.03%
342,447
+133,237
+64% +$275K
2023 Q4
10 quarters
IDYA icon
181
IDEAYA Biosciences
IDYA
$3.27B
$745K 0.03%
20,000
– –
2025 Q3
3 quarters
SIBN icon
182
SI-BONE Inc
SIBN
$873M
$734K 0.03%
45,000
+32,420
+258% +$463K
2026 Q1
1 quarter
AMLX icon
183
PUT
Amylyx Pharmaceuticals
AMLX
$3.39B
$720K 0.03%
+40,100
New +$620K
2026 Q2
0 quarters
RPRX icon
184
Royalty Pharma
RPRX
$26.3B
$701K 0.03%
12,500
+7,500
+150% +$390K
2026 Q1
1 quarter
EOLS icon
185
Evolus
EOLS
$477M
$694K 0.03%
100,000
+44,141
+79% +$261K
2025 Q4
2 quarters
RARE icon
186
CALL
Ultragenyx Pharmaceutical
RARE
$1.47B
$668K 0.03%
20,000
– –
2025 Q4
2 quarters
IBIO icon
187
iBio
IBIO
$50.2M
$657K 0.03%
375,531
-94,347
-20% -$169K
2025 Q2
4 quarters
FWRD icon
188
Forward Air
FWRD
$525M
$652K 0.03%
48,241
-30,000
-38% -$447K
2025 Q4
2 quarters
GERN icon
189
Geron
GERN
$765M
$647K 0.03%
505,817
+305,817
+153% +$431K
2023 Q4
10 quarters
SYK icon
190
Stryker
SYK
$108B
$630K 0.03%
+2,000
New +$630K
2026 Q2
0 quarters
NVO icon
191
CALL
Novo Nordisk
NVO
$168B
$623K 0.03%
13,000
– –
2026 Q1
1 quarter
IOVA icon
192
Iovance Biotherapeutics
IOVA
$6.44B
$608K 0.03%
+146,090
New +$555K
2026 Q2
0 quarters
MGNX icon
193
MacroGenics
MGNX
$211M
$600K 0.03%
129,822
+89,822
+225% +$340K
2026 Q1
1 quarter
GILD icon
194
Gilead Sciences
GILD
$190B
$587K 0.03%
4,648
-1,703
-27% -$224K
2025 Q4
2 quarters
NTRA icon
195
Natera
NTRA
$56.9B
$583K 0.03%
2,147
– –
2025 Q4
2 quarters
SPTX icon
196
Seaport Therapeutics
SPTX
$893M
$565K 0.03%
+26,000
New +$457K
2026 Q2
0 quarters
CRBP icon
197
CALL
Corbus Pharmaceuticals
CRBP
$85.3M
$563K 0.03%
60,000
+25,000
+71% +$237K
2026 Q1
1 quarter
ASMB icon
198
Assembly Biosciences
ASMB
$418M
$562K 0.03%
20,447
+500
+3% +$13.6K
2025 Q3
3 quarters
HELP
199
Helus Pharma Inc. Common Stock
HELP
$758M
$537K 0.02%
81,278
+50,000
+160% +$250K
2025 Q3
3 quarters
BNTC icon
200
Benitec Biopharma
BNTC
$289M
$535K 0.02%
40,000
+22,500
+129% +$267K
2026 Q1
1 quarter
6 7
8
9 10

Similar funds

GAMH
Greenwoods Asset Management (HK) Hong Kong $2.19B AUM 50.16% 1-Year Est. Return
RCAG
Rehmann Capital Advisory Group Lansing, Michigan $2.18B AUM 23.73% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $2.19B AUM 21.28% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $2.19B AUM 23.13% 1-Year Est. Return
TCM
Traynor Capital Management Malvern, Pennsylvania $2.18B AUM 62.36% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $2.18B AUM 13.58% 1-Year Est. Return
IAN
Integrated Advisors Network Dallas, Texas $2.18B AUM 30.3% 1-Year Est. Return
BOI
Bank of Italy Rome, Italy $2.2B AUM 1.53% 1-Year Est. Return

ADAR1 Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, ADAR1 Capital Management held 354 positions worth $2.19B, up 29% from $1.7B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

ADAR1 Capital Management deployed $166M of net new capital in Q2 2026, opening 43 new positions and adding to 102 existing holdings. Its largest new stake was Editas Medicine: 8,889,000 shares worth $28.8M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 88% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Denali Therapeutics, an estimated $17.3M trimmed.

  • ADAR1 Capital Management's largest Q2 2026 buy was Editas Medicine: 8,889,000 shares worth $28.8M.
  • ADAR1 Capital Management added most to Abivax in Q2 2026, an estimated $46.5M increase.
  • ADAR1 Capital Management's biggest Q2 2026 reduction was Denali Therapeutics, cutting an estimated $17.3M.
  • ADAR1 Capital Management fully exited Terns Pharmaceuticals in Q2 2026, selling an estimated $48.2M.
  • ADAR1 Capital Management's ten largest holdings make up 41% of its $2.19B portfolio in Q2 2026.
  • ADAR1 Capital Management opened 43 new positions and closed 78 in Q2 2026.
  • ADAR1 Capital Management's portfolio value rose 29% quarter-over-quarter to $2.19B.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.